Subashini Chandrapalan
Overview
Explore the profile of Subashini Chandrapalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandrapalan S, Phillips C, Newbery N, Logan S, Arasaradnam R
Clin Med (Lond)
. 2023 Dec;
23(6):637-640.
PMID: 38052464
We present the results of the 2022 Census of the Federation of Royal Colleges of Physicians of Edinburgh, Glasgow and London on whether physicians undertake research and the barriers they...
2.
Chandrapalan S, Arasaradnam R
Lancet Gastroenterol Hepatol
. 2023 Oct;
8(11):970.
PMID: 37837973
No abstract available.
3.
Krishnamoorthy A, Chandrapalan S, Ahmed M, Arasaradnam R
J Crohns Colitis
. 2023 Aug;
18(2):320-330.
PMID: 37540200
Background: Volatile organic compounds [VOCs] show promise as potential biomarkers of for ulcerative colitis and Crohn's disease, two chronic, idiopathic, gastrointestinal disorders with diagnostic and management challenges. Non-invasive biomarkers aid...
4.
Pelling M, Chandrapalan S, West E, Arasaradnam R
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190235
Background: Hepatobiliary cancers are notoriously difficult to detect, frequently leading to diagnosis in later stages of disease when curative treatment is not an option. The currently used biomarkers such as...
5.
Krishnamoorthy A, Chandrapalan S, JalayeriNia G, Hussain Y, Bannaga A, Lei I, et al.
Clin Med (Lond)
. 2023 Mar;
23(2):144-150.
PMID: 36921988
Background: Lateral flow tests (LFT) are point-of-care rapid antigen tests that allow isolation and control of disease outbreaks through convenient, practical testing. However, studies have shown significant variation in their...
6.
Krishnamoorthy A, Chandrapalan S, Bosch S, Bannaga A, de Boer N, de Meij T, et al.
Sensors (Basel)
. 2023 Feb;
23(3).
PMID: 36772415
(1) Background: Colorectal cancer is the second commonest cause of cancer deaths worldwide; recently, volatile organic compounds (VOCs) have been proposed as potential biomarkers of this disease. In this paper,...
7.
Chandrapalan S, Khasawneh F, Singh B, Lewis S, Turvill J, Persaud K, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230872
(1) Background: The service capacity for colonoscopy remains constrained, and while efforts are being made to recover elective services, polyp surveillance remains a challenge. (2) Methods: This is a multi-centre...
8.
Chandrapalan S, Bannaga A, Weidner A, Hitchins M, Arasaradnam R
Scand J Gastroenterol
. 2021 Dec;
57(4):473-480.
PMID: 34957898
Background: Hepatocellular carcinoma (HCC) lacks a suitable biomarker for minimally-invasive disease detection. Methylated (mSEPT9) is an emerging liquid biopsy test. We aimed to investigate recent studies that applied mSEPT9 for...
9.
Neilson L, Macdougall L, Lee P, Hardy T, Beaton D, Chandrapalan S, et al.
Frontline Gastroenterol
. 2021 Dec;
12(7):578-585.
PMID: 34917315
Background: Non-alcoholic fatty liver disease (NAFLD) is common and is associated with liver-related and cardiovascular-related morbidity. Our aims were: (1) to review the current management of patients with NAFLD attending...
10.
Amos G, Sergaki C, Logan A, Iriarte R, Bannaga A, Chandrapalan S, et al.
Sci Rep
. 2021 Sep;
11(1):18699.
PMID: 34548500
Understanding the variables that influence microbiome studies is critical for successful translational research. Inflammatory bowel disease (IBD) is a complex group of diseases that can present at multiple locations within...